It’s a development millions of people living with Type 1 diabetes never thought would happen. A new study is showing ...

Teplizumab is the disease-modifying therapy for type 1 diabetes and England is the first country in Europe to recommend it's use through a health technology appraisal.

Type 1 diabetes is characterized by immune-associated destruction of insulin producing pancreatic beta cells resulting in a lifelong reliance on insulin replacement. However, cardiovascular disease ...

GLP-1RA initiation in type 1 diabetes associated with lower risks of major cardiovascular events and end-stage kidney disease. Patients using GLP-1RAs more likely to achieve clinically meaningful ...

Children who were recently diagnosed with type 1 diabetes need less supplemental insulin to keep their blood sugar in a healthy range if they use the immunotherapy drug teplizumab, a new study reports ...

A new study has revealed the best types of exercise for patients with type-1 diabetes. A new study has revealed the best types of exercise for patients with type-1 diabetes. The research was led by ...

GSK3368715, a first-in-class, reversible inhibitor of type I protein methyltransferases (PRMTs) demonstrated anticancer activity in preclinical studies. This Phase 1 study (NCT03666988) evaluated ...

The NHS is set to provide a new type-1 diabetes therapy which delays the onset of the disease.